ERBB2 and prostate adenocarcinoma: Moreover, its combination with chemotherapy drugs is effective for lung cancer, etc., and it can also reduce the chemotherapy resistance rate of PC3 cells [110]; CCT018159 is a heat shock protein inhibitor, which can arrest the tumor cell cycle or induce apoptosis [111, 112]; FH535, as a β-catenin inhibitor, can inhibit the growth of DU145 cells [113]; Lapatinib can block the ErbB2 signaling pathway, and its combination with abiraterone can enhance the therapeutic effect [114, 115]; MG-132 can sensitize PRAD cells that are resistant to TRAIL [116].